Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den Eeckhout(Ghent University), Sarah Gerlo(Ghent University)
npj Vaccines
July 23, 2020
Cited by 27


Related Papers